Oxybutynin Improved Quality of Life for Breast Cancer Survivors

Treatment with oxybutynin chloride (Ditropan XL®; Janssen Pharmaceuticals) helped reduce the frequency and intensity of hot flashes for women who could not take hormone...

No Significant Improvement in Early-stage TNBC Patients Treated with Adjuvant Capecitabine

Treating patients who had early-stage triple-negative breast cancer (TNBC) with the chemotherapeutic agent capecitabine (Xeloda®; Genentech/Roche) after they completed surgery and standard chemotherapy did...

The Promise of CAR T-Cell Therapy

Chimeric  Antigen T-cell therapy or CAR T-cell therapy is one of the most promising types of immunotherapy.  Early results as well as experiences with...

KATHERINE Trial: Trastuzumab Emtansine Reduces Risk of Invasive Recurrence of Breast...

Results from the Phase III KATHERINE Clinical Trial (NCT01772472), supported by F. Hoffmann Genentech/Roche and presented at the San Antonio Breast Cancer Symposium (SABCS),...

Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma Shows Promise

Initial safety data from an ongoing proof-of-concept trial of JCARH125, an investigational BCMA-targeting CAR T being developed by Juno Therapeutics/Celgene Corporation) in patients with...

The Future of Medicine is Bright: Personalized Medicine, Predictive Analytics and...

Modern medicine is to change dramatically. Over the past 200 years medicine has seen extraordinary developments and advances. From microbiology to the sequencing of the...

Optimal Pain Control Hampered by Misconceptions about Opioids

A cross-sectional survey conducted at the Sarawak General Hospital in Malaysia shows that misconceptions about the use of strong opioids undermines optimal pain control...

ESMO Launches Partnership Designed to Promote Asian-European Collaboration In Rare Cancers...

Rare cancers inherently make it difficult to collect data, build clinical expertise and treat affected patients. The challenges to find cures for these cancers...

Australian Kazia Therapeutics Presents ‘Trial in Progress’ Data for Glioblastoma Study

Results for GDC-0084, an investigational drug being being developed by Australian- based and oncology-focused Kazia Therapeutics, were presented during the annual meeting of the...

Interim Phase II Results of DNX-2401 + Pembrolizumab for Glioblastoma ...

Preliminary results from the CAPTIVE / KEYNOTE-192 study (NCT02798406) dose escalation study evaluating a single intratumoral injection of DNX-2401 (tasadenoturev; DNAtrix) followed by standard...

Latest